These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27635632)

  • 21. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting antiviral treatment for hepatitis C.
    Holmes JA; Rutledge SM; Chung RT
    Lancet; 2019 Apr; 393(10179):1392-1394. PubMed ID: 30765125
    [No Abstract]   [Full Text] [Related]  

  • 24. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
    Eslam M; George J
    Hepatol Int; 2015 Jan; 9(1):5-8. PubMed ID: 25788373
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs?
    Wynter J; Stine JG; Shah NL
    Dig Liver Dis; 2016 Sep; 48(9):1101. PubMed ID: 27257048
    [No Abstract]   [Full Text] [Related]  

  • 27. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance.
    Beste LA
    JAMA Netw Open; 2019 Jun; 2(6):e194757. PubMed ID: 31173111
    [No Abstract]   [Full Text] [Related]  

  • 29. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
    McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
    Sorbera MA; Friedman ML; Cope R
    J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.
    Maan R; Feld JJ; Duarte-Rojo A
    Aliment Pharmacol Ther; 2017 Aug; 46(3):379-380. PubMed ID: 28677289
    [No Abstract]   [Full Text] [Related]  

  • 33. Letter: should direct-acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus-infected patients with cancer? Authors' reply.
    Economides MP; Shigle TL; Torres HA
    Aliment Pharmacol Ther; 2017 Mar; 45(5):758-759. PubMed ID: 28150452
    [No Abstract]   [Full Text] [Related]  

  • 34. [Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
    Weiland O
    Lakartidningen; 2014 Nov; 111(51-52):2280-1. PubMed ID: 25423337
    [No Abstract]   [Full Text] [Related]  

  • 35. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral hepatitis: impressive advances but still a long way to eradication of the disease.
    Marcellin P; Asselah T
    Liver Int; 2014 Feb; 34 Suppl 1():1-3. PubMed ID: 24373070
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C.
    Sud R; Tiwari N; Forner P; Dowdell L; Freiman J; Zekry A
    Intern Med J; 2018 Jan; 48(1):105-106. PubMed ID: 29314510
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter: chronic hepatitis C genotype 3 infection - still a hurdle toward a direct-acting anti-viral-induced HCV cure?
    Bruno G; Milella M; Angarano G; Saracino A
    Aliment Pharmacol Ther; 2017 May; 45(10):1376-1377. PubMed ID: 28417495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.